Tests liraglutide in people with a form of inherited diabetes called MODY
Tests liraglutide, a diabetes medicine, in people with MODY and stomach problems.
Key facts
- Who runs it
- Mansa
- Where
- Cincinnati, United StatesSee the site
- Trial code
- Registry title
- Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 50 people, planned
- Started
- 8 May 2025
- Expected to end
- Jan 2027
- Type of study
- Interventional
- Treatments tested
- Liraglutide
- Record updated
- 17 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with maturity-onset diabetes of the young (MODY) confirmed by genetic testing. It studies the drug liraglutide.
- Age
- 10 years and older
- Sex
- All sexes can join.
- Disease stage
- MODY diagnosed by genetic testing, with HgbA1c above 6.5% (48 mmol/mol) (and not above 10.0% (86 mmol/mol)).
- Earlier treatment
- People already taking GLP-1 receptor agonists or stimulant-class medications cannot join. People who have had bariatric surgery cannot join.
- Biomarker or test result
- A MODY diagnosis confirmed by genetic testing.
Main reasons for not taking part
- History of anaphylaxis to GLP-1 receptor agonists
- Personal or family history of cancer, especially medullary thyroid cancer
- Personal history of pancreatitis or gene variants linked to a higher risk of pancreatitis
- Known active kidney disease
- Currently pregnant
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Diagnosis of MODY via genetic testing
- HgbA1c >6.5%
Who cannot take part
- on medications within the stimulant class
- have had bariatric surgery
- History of anaphylaxis to GLP-1 receptor agonists
- personal or family history of cancer, especially medullary thyroid cancer
- personal history of pancreatitis or pathogenic variants associated with increased risk of pancreatitis
- known active kidney disease
- severe hypoglycemia (glucose < 50 mg/dL) within 3 months of study enrollment
- HbA1c > 10.0%
- Already taking GLP-1 receptor agonists
- episode of diabetic ketoacidosis (DKA) in the past 3 months
- are currently pregnant
- BMI < 18.5 kg/m2 and pediatric patients with BMI < 5th percentile
Where in United States
- Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Lily DengTaking people
About the trial
What the trial wants to find out
The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY).
Read full original descriptionShow less
The investigators are interested in better understanding the way that this drug affects the metabolism and hormone levels of a person with MODY. Many people with MODY report having gastrointestinal (GI) issues such as an upset stomach. Investigators also are interested in finding out if this drug will help with GI issues.
If liraglutide does help with this symptom of MODY, the investigators want to know why this happens. If this drug is effective for participants, the investigators will use participants cells to make human induced pluripotent stem cell (iPSC). This means that the investigators will use participant cells to create what are called stem cells, which are cells in the body that are able to be told what their job is. Investigators will use these cells to see what happens in gastrointestinal (GI) tract.
The group in the trial
- liraglutide treatmentTreatment being tested
After baseline evaluation of enteroendocrine levels and metabolism, study participants will be prescribed liraglutide. Titration of liraglutide will be as follows: 1) Starting dose of liraglutide 0.6 mg daily for 1 week, 2) Increase to liraglutide 1.2 mg daily for 1 week, and 3) Maintain at final dose of liraglutide 1.8 mg daily. If study participants are unable to tolerate liragultide 1.8 mg daily due to side effects for 1 week, then will decrease back to liraglutide 1.2 mg daily.
Treatment: Liraglutide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Investigating Enteroendocrine Dysfunction, Metabolism, and Response to Liraglutide in Patients With Maturity-onset Diabetes of the Young (MODY)
- Plain-language title
- Tests liraglutide in people with a form of inherited diabetes called MODYGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 17 December 2025